IMPRIMIS PHARMACEUTICALS INC's ticker is IMMY and the CUSIP is 45323A201. A total of 20 filers reported holding IMPRIMIS PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $125,000 | -13.2% | 49,858 | +31.5% | 0.00% | – |
| Q3 2016 | $144,000 | +16.1% | 37,907 | +14.9% | 0.00% | – |
| Q2 2016 | $124,000 | +51.2% | 32,979 | +59.5% | 0.00% | – |
| Q1 2016 | $82,000 | -47.1% | 20,679 | -7.6% | 0.00% | – |
| Q4 2015 | $155,000 | +9.9% | 22,370 | +2.1% | 0.00% | – |
| Q3 2015 | $141,000 | -15.1% | 21,908 | +7.0% | 0.00% | – |
| Q2 2015 | $166,000 | +15.3% | 20,474 | +13.6% | 0.00% | – |
| Q1 2015 | $144,000 | 0.0% | 18,018 | -6.3% | 0.00% | – |
| Q4 2014 | $144,000 | +8.3% | 19,234 | +7.7% | 0.00% | – |
| Q3 2014 | $133,000 | 0.0% | 17,866 | -6.7% | 0.00% | – |
| Q2 2014 | $133,000 | +6.4% | 19,158 | +2.9% | 0.00% | – |
| Q1 2014 | $125,000 | +257.1% | 18,614 | +78.5% | 0.00% | – |
| Q4 2013 | $35,000 | -22.2% | 10,428 | +4.4% | 0.00% | – |
| Q3 2013 | $45,000 | -42.3% | 9,988 | +8.6% | 0.00% | – |
| Q2 2013 | $78,000 | – | 9,196 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 1,205,000 | $9,797,000 | 3.90% |
| Granite Investment Partners, LLC | 129,627 | $1,054,000 | 0.10% |
| MARATHON CAPITAL MANAGEMENT | 25,000 | $203,000 | 0.09% |
| Granite Point Capital Management, L.P. | 22,673 | $184,000 | 0.05% |
| Financial Architects, Inc | 4,000 | $33,000 | 0.01% |
| REGIONS FINANCIAL CORP | 30,500 | $248,000 | 0.00% |
| DEUTSCHE BANK AG\ | 2,800 | $22,000 | 0.00% |
| GOLDMAN SACHS GROUP INC | 14,306 | $116,000 | 0.00% |
| MORGAN STANLEY | 17 | $0 | 0.00% |
| Tower Research Capital LLC (TRC) | 103 | $1,000 | 0.00% |